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Objective: To study the diagnostic and treatment modalities used in
drug allergy/hypersensitivity among members of the World Allergy
Organization (WAO).
Methods: A questionnaire comprising 39 questions was circulated
electronically to member societies, associate member societies, and
regional and afﬁliate organizations of WAO between June 29, 2009,
and August 9, 2009.
Results: Eighty-two responses were received. Skin testing was used
by 74.7%, with only 71.4% having access to penicillin skin test
reagents. In vitro–speciﬁc IgE tests were used by 67.4%, and basophil
activation test was used by 54.4%. Lymphocyte transformation tests
were used by 36.8% and patch tests by 54.7%. Drug provocation tests
were used by 68.4%, the most common indication being to exclude
hypersensitivity where history/symptoms were not suggestive of drug
hypersensitivity/allergy (76.9%). Rapid desensitization for chemother-
apy, antibiotics, or biologic agents was used by 69.6%. Systemic
corticosteroid was used in the treatment of Stevens–Johnson syndrome
by 72.3%, and high-dose intravenous immunoglobulins in toxic
epidermal necrolysis by 50.8%. Human leukocyte antigen screening
before prescription of abacavir was used by 92.9% and before pre-
scription of carbamazepine by 21.4%.
Conclusions: Results of this survey form a useful framework for
developing educational and training needs and for improving access
to drug allergy diagnostic and treatment modalities across WAO
member societies.
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Drug allergy/hypersensitivity1 is a common problem seenby general and subspecialty adult and pediatric outpatient
clinics,2 inpatient wards,3 and emergency department.4 Among
specialists, patients with drug allergy/hypersensitivity may
present to an allergologist,5 dermatologist, or other organ-based
specialist depending on the type, extent, and severity6–9 of
clinical manifestations. Although guidelines for the diagnosis,
evaluation, and treatment of drug allergy/hypersensitivity have
been available for more than a decade, clinical practice is het-
erogenous across the world and indeed even within districts/
regions in the same country. This may be inﬂuenced by different
origins of undergraduate and postgraduate allergological train-
ing (dermatology, pulmonology, or allergy/immunology10,11),
type of allergological practice (private, government practice,
clinical or research-based institution), funding mechanisms,
accessibility to various types of diagnostic tests, availability of
basic versus tertiary practice infrastructure/laboratory equip-
ment, and many other factors.12
OBJECTIVE
The objective of this survey was to study the
diagnostic and treatment modalities used in drug allergy/
hypersensitivity among members of the World Allergy
Organization (WAO), with the results forming the frame-
work for developing the educational and training needs and
for improving access to drug allergy diagnostic and treat-
ment modalities across WAO member societies. The speciﬁc
aims of this survey were
1. To increase the global awareness on the requirement of
specialized/dedicated allergy clinics/centers for drug
allergy testing and management;
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2. To lay foundations toward a globally standardized clin-
ical practice of drug allergy management;
3. To train allergists in performing diagnostic tests;
4. To facilitate exchanges of knowledge and collaborations
among allergy centers in different countries.
METHODS
The questionnaire was initiated and circulated to
members of the WAO Drug Allergy Special Committee
for evaluation in January 2009. The questions covered
both diagnostic and therapeutic practices in drug allergy/
hypersensitivity. The ﬁnal questionnaire comprised a total
of 39 questions, which was approved by the entire
committee (Appendix 1).
The questionnaire was then converted into a Web-
based questionnaire by the WAO Secretariat and sent
electronically to 77 regional and national member societies
of WAO. If representatives of member societies were unable
to complete the speciﬁc questions on diagnostic tests and
therapies available in their own country/region, they were
asked to recommend the questionnaire to centers that would
be able to respond to the questions. All respondents were
given 6 weeks (June 29, 2009 to August 9, 2009) to reply.
The responses were then collated by the WAO Secretariat,
and the numbers and percentages of respondents for each
question were collated.
RESULTS
There were a total of 82 responses comprising respond-
ents from WAO member societies (95%), associate member
societies (3.7%), regional organizations (3.7%), and afﬁliate
organizations (1.1%). There were 13 additional responses
from individuals who were recommended by the WAO
member society representative who was not able to complete
the speciﬁc questions on diagnostic tests and therapies
available in the country/region. The geographical origin of
all respondents was Europe (49.1%), Asia Paciﬁc (26.4%),
Latin America (15.1%), North America (5.7%), and Africa/
Middle East (3.7%).
Among all responders, 95.3% and 55.6% responded
that dedicated allergy clinics and dermatology clinics,
respectively, in their country conducted evaluations for drug
allergy/hypersensitivity. Among responders, 61.8% practiced
in countries/regions where there were drug allergy centers/
clinics dedicated to adult care, and 64.7% practiced where
such centers dedicated to pediatric care were available.
The most widely used clinical practice guideline was
the American Academy of Allergy Asthma and Immunology/
American College of Allergy, Asthma and Immunology
(AAAAI/ACAAI) 2008 Practice Parameter Update: Allergy
diagnostic testing13 (59.7%), followed by the European Acad-
emy of Allergy Asthma and Clinical Immunology (EAACI)
guidelines on provocation tests for aspirin and other
drugs14,15 (41.6%). The remaining guidelines used16–26 are
summarized in Table 1.
For immediate reactions, skin testing was used by
74.7%, with the majority (67.6%) using this for both clinical
care and research. Only 71.4% had access to penicillin skin test
reagents, where the commercial Diater product (Diater Labo-
ratories, Madrid, Spain) for penicilloyl polylysine and minor
determinant mix was used by 49.1% and in-house reagents by
26.3%. Drugs that were commonly skin tested were penicillins
(87.5%), cephalosporins (77.8%), local anesthetic agents
(75.0%), general anesthetic agents (61.1%), and non–beta-lac-
tam antibiotics (50.0%) (Table 2). Drugs for skin testing were
prepared by the allergist in 65.3%, nurse practitioner/specialist
in 34.7%, and pharmacist in 27.8%. Among some respondents,
there was more than 1 practitioner who could prepare the drugs
for skin testing. Negative skin tests were followed by a drug
provocation test (DPT) in only 56.2% of cases.
In vitro–speciﬁc IgE tests were used by 67.4% of
respondents. The tests commercially available were the
immunoCAP-ﬂuorescent enzyme immunoassay (CAP-
FEIA) (previously Pharmacia now called Phadia, Uppsala,
Sweden) in 80.6%, radioallergosorbent test (RAST) in
56.5%, ﬂow cytometric cellular allergen stimulation test
(Buhlmann Labs, Switzerland) in 25.8%, cellular allergen
stimulation test enzyme-linked immunosorbent assay
(CAST-ELISA) (Buhlmann Labs) in 24.2%, and ﬂow
cytometry-2-cellular allergen stimulation test (Flow-2-
CAST) (Buhlmann Labs) in 14.5% (Table 3). In-house
assays most commonly used were radioallergosorbent test
(48.6%) and radioimmunoassays (22.9%). The most com-
monly tested drugs were penicillins (93.7%), cephalospor-
ins (61.9%), general anesthetic agents (36.5%), and
nonsteroidal anti-inﬂammatory drugs (NSAID) (27.0%).
Other tests available to respondents included serum total
tryptase in 75.0% and basophil activation test in 54.4%.
For nonimmediate reactions, lymphocyte transforma-
tion tests (LTTs) were used by 36.8% of respondents, the
majority for both clinical care and research (48.6%) but more
for research (37.1%) than for clinical care (14.3%) alone.
Where available, in-house LTT was used by 52.9%, sent to
another facility in the same region/country by 32.4%, and sent
out of the region/country by 14.7%. The drugs most
commonly tested using LTT were beta-lactam antibiotics
(77.8%), non–beta-lactam antibiotics (58.3%), and NSAID/
selective cyclooxygenase inhibitors (36.1%). The other drugs
commonly tested are listed in Table 4. The types of nonim-
mediate reactions most commonly tested using LTT were
drug-induced hypersensitivity syndrome (DIHS) (65.6%),
Stevens–Johnson syndrome (SJS) (65.6%), maculopapular
exanthema (46.9%), acute generalized exanthematous pustu-
losis (AGEP) (46.9%), and toxic epidermal necrolysis (TEN)
(46.9%). The other types of nonimmediate reactions com-
monly tested using LTT are shown in Table 5.
Patch tests were used for both clinical care and research
(59.6%) but more for clinical care (30.8%) than for research
(9.6%) alone. Commercialized form of the drug was used by
55.3%, the pure substance by 21.3%, and both by the
remaining 23.4%. The most common dilutions were 1%
(34.2%) and 5% (31.6%), with majority using petrolatum
(90.0%). Drugs used for patch testing were obtained commer-
cially by 55.3%, prepared in-house by 34.0%, and obtained
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from both sources in the remaining 10.7%. In addition to the
parent drug, 53.3% also tested components other than the
parent drug including preservative (44.4%), coloring (37.8%),
and excipient (28.9%). Patch test reading was done, and read at
20 minutes by 4.2%, 48 hours by 47.9%, 96 hours by 10.4%,
and on day 7 (if days 2 and 4 are negative) by 37.5%.
Photopatch tests were done by only 46.5% of respondents.
Drugs most commonly used for patch testing were beta-lactam
antibiotics (83.3%), non–beta-lactam antibiotics (64.6%), and
corticosteroids (60.4). The drugs commonly patch tested are
shown in Table 6. Patch tests were most commonly used in the
diagnosis of maculopapular exanthema (66.0%), DIHS
(63.8%), ﬁxed drug eruption (61.7%), and AGEP (55.3%).
The other types of nonimmediate reactions for which patch
tests were commonly used are shown in Table 7.
DPTs were used by 68.4% with the most common
indication being to exclude hypersensitivity where the history
was not suggestive or the symptoms not speciﬁc for drug
hypersensitivity/allergy (76.9%). It was used for deﬁnitive
diagnosis where history was suggestive but allergological
tests were negative, nonconclusive or not available by 67.7%;
to exclude cross-reactivity of related drugs in proven
hypersensitivity (eg, cephalosporin in a penicillin allergic
individual) by 63.1%; and to provide safe pharmacologically/
structurally nonrelated drugs in proven hypersensitivity
(e.g. beta-lactams) by 60.0%. This is summarized in Table 8.
TABLE 1. Commonly Used Clinical Guidelines
Europe,
n (%)
Asia Paciﬁc,
n (%)
North America,
n (%)
Latin America,
n (%)
Africa Middle
East, n (%)
Total
(n ¼ 77)
AAAAI/ACAAI 2008 Practice Parameter Update:
Allergy diagnostic testing13
14 (18.2) 16 (19.5) 6 (7.8) 7 (9.1) 3 (3.9) 46 (59.7)
EAACI/GA2LEN 2007: Aspirin provocation tests
for aspirin hypersensitivity14
20 (26.0) 3 (3.9) 2 (2.6) 5 (6.5) 2 (2.6) 32 (41.6)
ENDA 2003 Guidelines: DPTs15 21 (27.3) 6 (7.8) 1 (1.3) 3 (3.9) 1 (1.3) 32 (41.6)
ENDA 2006: Statement on penicillin skin testing17 17 (22.1) 4 (5.2) 1 (1.3) 4 (5.2) 2 (2.6) 28 (36.4)
ENDA 2004 Guidelines: Non-immediate allergic
reactions to beta-lactam antibiotics18
19 (24.7) 4 (5.2) 1 (1.3) 3 (3.9) 1 (1.3) 28 (36.4)
ENDA 2003 Guidelines: Immediate allergic
reactions to beta-lactam antibiotics19
18 (23.4) 4 (5.2) 1 (1.3) 3 (3.9) 1 (1.3) 27 (35.1)
BSACI 2009 Guidelines: Management of
drug allergy16
12 (15.6) 11 (14.3) 0 (0.0) 2 (2.6) 1 (1.3) 26 (33.8)
ENDA 2005 Guidelines: Management of
hypersensitivity to iodinated contrast media20
18 (23.4) 2 (2.6) 1 (1.3) 3 (3.9) 1 (1.3) 25 (32.5)
AAAAI/ACAAI 1999 Practice Parameter:
Drug hypersensitivity21
6 (7.8) 9 (11.7) 3 (3.9) 4 (5.2) 3(3.9) 25 (32.5)
AAAAI/ACAAI 2006 Practice Parameter:
Contact dermatitis22
10 (13.0) 3 (3.9) 4 (5.2) 4 (5.2) 1 (1.3) 22 (28.6)
SFAR/ENDA 2005 Guidelines: Reducing the
risk of anaphylaxis during anaesthesia23
13 (16.9) 4 (5.2) 1 (1.3) 2 (2.6) 1 (1.3) 21 (27.3)
European Society of Contact Dermatitis 2001
Guidelines for the study of skin testing in
investigating CADR24
13 (16.9) 3 (3.9) 2 (2.6) 1 (1.3) 1 (1.3) 20 (26.0)
International Contact Dermatitis Research Group
(ICDRG) 1970: Criteria for patch test reading25
5 (6.5) 5 (6.5) 3 (3.9) 3 (3.9) 1 (1.3) 17 (22.1)
BSACI 2003 Guidelines: Suspected anaphylactic
reactions associated with anaesthesia26
4 (5.2) 5 (6.5) 0 (0.0) 1 (1.3) 0 (0.0) 10 (13.0)
Percentage represents percentage of all 77 respondents who answered this question.
TABLE 2. Drugs Commonly Skin Tested
Europe,
n (%)
Asia Paciﬁc,
n (%)
North America,
n (%)
Latin America,
n (%)
Africa Middle
East, n (%)
Region Not
Speciﬁed, n (%)
Total (n ¼ 72),
n (%)
Penicillins 26 (36.1) 15 (20.8) 6 (8.3) 8 (11.1) 6 (8.3) 2 (2.6) 63 (87.5)
Cephalosporins 25 (34.7) 14 (19.4) 6 (8.3) 7 (9.7) 2 (2.6) 2 (2.6) 56 (77.8)
Local anesthetic agents 28 (38.9) 8 (11.1) 7 (9.7) 7 (9.7) 2 (2.6) 2 (2.6) 54 (75.0)
General anesthetic agents 25 (34.7) 4 (5.6) 4 (5.6) 7 (9.7) 2 (2.6) 2 (2.6) 44 (61.1)
Non-beta lactam antibiotics 21 (29.2) 6 (8.3) 3 (4.2) 4 (5.6) 1 (1.4) 1 (1.4) 36 (50.0)
Non-steroidal anti-inﬂammatory drugs 15 (20.8) 6 (8.3) 2 (2.6) 4 (5.6) 1 (1.4) 1 (1.4) 29 (40.3)
Percentage represents percentage of all 72 respondents who answered this question.
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Preparation of drugs for challenges was performed by the doctor
(62.1%), pharmacist (39.4%), and nurse practitioner (25.8%),
respectively. Challenges used were most commonly open chal-
lenges (75.4%), followed by single-blind placebo-controlled
(44.6%), or double-blind placebo-controlled (24.6%). Oral chal-
lenges were more commonly used compared with parenteral
challenges. Among oral challenges, the most commonly used
formulations were tablet (80%), capsule (73.8%), or syrup
(61.5%). Among parenteral challenges, subcutaneous challenges
(49.2%) were more commonly done compared with intravenous
(27.7%) and intramuscular (21.5%) routes.
In the survey on therapies for drug allergy, rapid
desensitizations for the treatment of IgE-mediated and non–
IgE-mediated anaphylactic reactions to chemotherapy, anti-
biotics, or biologic agents, such as monoclonal antibodies,
were used by 69.6% of respondents. Systemic corticosteroids
were used by 72.3% for the treatment of SJS and/or systemic
manifestations of TEN, high-dose intravenous immunoglobu-
lins for TEN by 50.8%, and other immunosuppressive drugs
by 9.2% (most commonly cyclosporine). Comanagement
with an intensive care/high-dependency/burns unit was com-
monly practiced by 67.7% of respondents, whereas coman-
agement with an ophthalmologist (49.2%), daily pain
assessment and management (36.9%), and the use of the
Severity of Illness Score for TEN for prognostication during
the ﬁrst 24 hours (29.2%) were less frequently practiced.
Human leukocyte antigen (HLA) testing for speciﬁc
drugs associated with severe cutaneous adverse reactions
(SCAR) before prescription was reported by 14 respondents
(17.1%). Of these, 92.9% of respondents from the American,
Australasian, Austrian, Azerbaijan, Chilean, Columbian,
Dutch, French, and Swiss societies screened for HLA-
B*5701 in white ancestry before the prescription of abacavir.
There were 21.4% of respondents from the Australasian, Chi-
nese, and Dutch societies who screened for HLA-B*1502 in
Han Chinese or people with Asian ancestry before the pre-
scription of carbamazepine. None of the respondents screened
for HLA-B*5801 before the prescription of allopurinol in
Han Chinese.
DISCUSSION
There was a good response rate for this survey,
reﬂecting signiﬁcant interest in the diagnosis and manage-
ment of drug allergy/hypersensitivity among WAO member
organizations. Most regions used existing guidelines and
practice parameters from their own (where available) and
those from other international allergy/immunology member
groups and regional organizations.
There were more respondents who did not have
dedicated pediatric drug allergy services in their region
compared with adult drug allergy clinics. First, this could be
due to children with drug allergy/hypersensitivity being usually
seen within general pediatric or general pediatric allergy
clinics, in contrast to adult internal medicine/specialty services,
which tend to be more subspecialized. Second, most clinical
and research groups in pediatric allergology tend to focus more
on pediatric asthma, eczema, rhinitis, food allergy, and
anaphylaxis rather than drug allergy/hypersensitivity27–31.
TABLE 3. Commercially Available In Vitro–Speciﬁc IgE Tests
Europe,
n (%)
Asia Paciﬁc,
n (%)
North America,
n (%)
Latin America,
n (%)
Africa Middle
East, n (%)
Region Not
Speciﬁed, n (%)
Total (n ¼ 62),
n (%)
CAP-FEIA 25 (40.3) 9 (14.5) 6 (9.7) 3 (4.8) 4 (6.5) 3 (4.8) 50 (80.6)
RAST 18 (29.0) 3 (4.8) 4 (6.5) 3 (4.8) 4 (6.5) 3 (4.8) 35 (56.5)
CAST-ELISA 10 (16.1) 1 (1.6) 0 (0.0) 2 (3.2) 2 (3.2) 1 (1.6) 16 (25.8)
FLOW-CAST 11 (17.7) 1 (1.6) 1 (1.6) 0 (0.0) 0 (0.0) 2 (3.2) 15 (24.2)
FLOW-2-CAST 8 (11.1) 0 (0.0) 1 (1.6) 0 (0.0) 2 (3.2) 2 (3.2) 9 (14.5)
Percentage represents percentage of all 72 respondents who answered this question.
CAP-FEIA, immunoCAP ﬂuorescent enzyme immunoassay; CAST-ELISA, cellular allergen stimulation test enzyme-linked immunosorbent assay; FLOW-CAST, ﬂow cytometry
cellular allergen stimulation test; FLOW-2-CAST: ﬂow cytometry-2-cellular allergen stimulation test; RAST, radio allergosorbent test.
TABLE 4. Drugs Commonly Tested Using LTT
Europe,
n (%)
Asia Paciﬁc,
n (%)
North America,
n (%)
Latin America,
n (%)
Africa Middle
East, n (%)
Region Not
Speciﬁed, n (%)
Total (n ¼ 36),
n (%)
Antibiotics (beta-lactams) 19 (52.8) 3 (8.3) 3 (8.3) 1 (2.8) 1 (2.8) 1 (2.8) 28 (77.8)
Antibiotics (Non beta-lactams) 14 (38.9) 2 (5.6) 3 (8.3) 1 (2.8) 1 (2.8) 0 (0.0) 21 (58.3)
NSAIDs and Selective Cox-2 inhibitors 11 (30.6) 1 (2.8) 1 (2.8) 0 (0.0) 0 (0.0) 0 (0.0) 13 (36.1)
Anti-epileptics 11 (30.6) 0 (0.0) 1 (2.8) 0 (0.0) 0 (0.0) 0 (0.0) 12 (33.3)
Anti-tuberculous drugs 8 (22.2) 1 (2.8) 0 (0.0) 1 (2.8) 1 (2.8) 0 (0.0) 11 (30.6)
Pyrazolones 8 (22.2) 1 (2.8) 0 (0.0) 0 (0.0) 0 (0.0) 2 (5.6) 11 (30.6)
Local anesthetic agents 8 (22.2) 1 (2.8) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.8) 10 (27.8)
Neuromuscular blockers 6 (16.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (5.6) 8 (22.2)
Percentage represents percentage of all 36 respondents who answered this question.
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Third, children present, in general, with less complex drug-
related allergies than adults because they do not tend to take
many drugs at the same time. Although the principles of when
and how to evaluate children with suspected drug allergy is no
different from adults,32,33 pragmatically, testing in children is
mainly recommended if no alternative drug is available and
there is an absolute requirement for that speciﬁc drug to be
administered. There are logistic constraints as intradermal test-
ing and DPTs may be difﬁcult to perform on children, espe-
cially the very young. Even if drug allergy is documented in
childhood, full retesting is often necessary once the adult age is
reached. This pragmatic approach has not, however, reached
unanimous consensus among allergists.
Skin tests (74.7%) and in vitro blood tests (67.4%) were
commonly used in the diagnosis of immediate reaction, with
beta-lactam antibiotics and anesthetic agents being the most
commonly tested. However, only 70% of respondents had
access to penicillin skin test reagents. Benzylpenicilloyl-
polylysine, a major penicillin skin test reagent commercially
known in the United States as, was not commercially
available after September 2003. Hollister-Stier, the sole
producer of PrePen in the United States, was directed by
the Food and Drug Administration to cease its production
in 2003 because of the lack of a dedicated penicillin
manufacturing facility and hence quality concerns. A product
containing major and minor determinants (Allergopen) was
available on the European market until 2004, then it was also
withdrawn by Merck worldwide.17 Thus, major and minor pen-
icillin determinants produced commercially by Diater S.A.
(Madrid, Spain) were used in several European and Asian
countries with comparable performance characteristics com-
pared with PrePen and Allergopharma kit.34–37 In September
2009, ALK-Abelló and AllerQuest, LLC announced the return
of PrePen to the United States and the international market.
With this, penicillin skin testing is likely to become more
widely available among WAO member societies again.
Although intradermal tests (IDTs) are used in the
diagnosis of immediate reactions,13 the delayed IDT reading
usually at 24 hours and 72 hours is useful in the diagnosis of
nonimmediate reactions38 and has been recommended in
guidelines on the evaluation of drug allergy,16 for instance,
for nonimmediate reactions to beta-lactam antibiotics.18 How-
ever, this survey did not look speciﬁcally at the number of sites
that carried out delayed IDT readings.
For nonimmediate reactions, patch tests were used more
commonly (54.7%) compared with LTT (36.8%). The use of
patch tests and LTT is more common in Europe compared
with other regions of the world. A positive patch test or
LTT is useful, but a negative test cannot exclude drug
allergy/hypersensitivity. Patch tests preparations are not well
TABLE 5. Types of Nonimmediate Reactions Commonly Tested Using LTT
Europe,
n (%)
Asia Paciﬁc,
n (%)
North America,
n (%)
Latin America,
n (%)
Africa Middle
East, n (%)
Region Not
Speciﬁed, n (%)
Total (n ¼ 32),
n (%)
DIHS 16 (50.0) 1 (3.1) 1 (3.1) 2 (6.3) 1 (3.1) 0 (0.0) 21 (65.6)
SJS 14 (43.8) 1 (3.1) 2 (6.3) 0 (0.0) 0 (0.0) 4 (12.5) 21 (65.6)
Maculopapular exanthema 11 (34.3) 1 (3.1) 2 (6.3) 0 (0.0) 0 (0.0) 1 (3.1) 15 (46.9)
AGEP 14 (43.8) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (3.1) 15 (46.9)
TEN 11 (34.3) 1 (3.1) 1 (3.1) 0 (0.0) 0 (0.0) 2 (6.3) 15 (46.9)
Fixed drug eruption 7 (21.9) 2 (6.3) 1 (3.1) 1 (3.1) 1 (3.1) 1 (3.1) 13 (40.6)
Immunbullous eruptions 9 (28.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (3.1) 10 (31.3)
Vasculitis 6 (18.8) 1 (3.1) 0 (0.0) 1 (3.1) 1 (3.1) 0 (0.0) 9 (28.1)
Hepatitis 4 (12.5) 1 (3.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 5 (15.6)
Blood dyscracias 2 (6.3) 1 (3.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (9.4)
Interstitial nephritis 1 (3.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (3.1)
Percentage represents percentage of all 32 respondents who answered this question.
TABLE 6. Drugs Commonly Tested Using Patch Tests
Europe,
n (%)
Asia Paciﬁc,
n (%)
North America,
n (%)
Latin America,
n (%)
Africa Middle
East, n (%)
Region Not
Speciﬁed, n (%)
Total (n ¼ 48),
n (%)
Antibiotics (beta-lactams) 22 (45.8) 6 (12.5) 4 (8.3) 6 (12.5) 3 (6.3) 1 (2.1) 40 (83.3)
Antibiotics (non–beta-lactams) 19 (39.6) 1 (2.1) 4 (8.3) 5 (10.4) 2 (4.2) 0 (0.0) 31 (64.6)
Corticosteroids 20 (41.7) 3 (6.3) 2 (4.2) 3 (6.3) 1 (2.1) 0 (0.0) 29 (60.4)
Anti-epileptics 19 (39.6) 1 (2.1) 2 (4.2) 5 (10.4) 0 (0.0) 1 (2.1) 28 (58.3)
Cotrimoxazole 16 (33.3) 1 (2.1) 2 (4.2) 3 (6.3) 0 (0.0) 0 (0.0) 22 (45.8)
NSAIDs and Selective Cox-2 inhibitors 13 (27.1) 3 (6.3) 2 (4.2) 3 (6.3) 1 (2.1) 1 (2.1) 21 (43.8)
Anti-tuberculous drugs 12 (25.0) 1 (2.1) 1 (2.1) 2 (4.2) 0 (0.0) 1 (2.1) 17 (35.4)
Radiocontrast media 13 (27.1) 1 (2.1) 1 (2.1) 1 (2.1) 0 (0.0) 0 (0.0) 16 (33.3)
Acyclovir 11 (22.9) 0 (0.0) 1 (2.1) 2 (4.2) 0 (0.0) 0 (0.0) 14 (29.2)
Percentage represents percentage of all 48 respondents who answered this question.
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standardized across all drugs, seem to be useful only in
certain types of drug eruptions (eg, exanthema, eczema, and
AGEP) but not others (eg, TEN), and are useful only with
certain drugs.38,39 The same is true for LTT, which has been
found to be useful in exanthema, AGEP, bullous exanthema,
drug rash with eosinophilia and systemic symptoms, and only
for certain drugs. Many of the respondents, mainly from
Europe, used patch tests and LTT in diagnosing the putative
drug for severe reactions (SJS, TEN, DIHS). The many dis-
advantages for LTT including the requirement for sterile cell
cultures, long time required to run the test, use of radioactiv-
ity, and expensive equipment limit its use to specialized ter-
tiary clinical and research centers.40
DPTs were used by 68.4% of respondents with the most
common indication being to exclude hypersensitivity where
the history was not suggestive or the symptoms not speciﬁc
for drug hypersensitivity/allergy (76.9%). DPT is generally
safe when properly carried out under supervision and with
constant, careful patient assessment41 both in adults42 and in
children.43 It is most commonly used in the deﬁnitive diag-
nosis of beta-lactam (penicillin or cephalosporin) allergy,44–46
or demonstration of tolerance to alternative NSAIDsdweak
COX-1 inhibitors (paracetamol) and/or preferential (meloxicam)
or highly selective COX-2 inhibitors (etoricoxib, parecoxib)din
patients with NSAID/aspirin exacerbated respiratory disease,
urticaria/angioedema, or NSAID intolerance.47–51
Deﬁnitive treatment of drug allergy includes avoidance
of the drug in question, patient education on prevention,
knowledge of potentially cross-reacting drugs, and giving
patients some form of medic alert identiﬁcation or notiﬁcation.
The survey looked at 2 speciﬁc treatment modalities: drug
desensitization and management of SCAR (SJS/TEN/DIHS).
Rapid desensitizations, carried out by 69.6% of respond-
ents, has been described for the treatment of IgE-mediated and
non–IgE-mediated anaphylactic reactions to chemotherapy, anti-
biotics, or biologic agents, such as monoclonal antibodies,52–54
and to high-dose aspirin in aspirin exacerbated respiratory
disease55 and low-dose aspirin (desensitization rechallenge) in
patients with coronary artery disease requiring percutaneous
coronary intervention.56–58
The management of SJS/TEN59 was variable across
different respondents, among whom 72.3% used systemic
corticosteroids in SJS and/or systemic manifestations of
TEN, 50.8% used high-dose intravenous immunoglobulin
TABLE 7. Types of Nonimmediate Reactions Commonly Tested Using Patch Tests
Europe,
n (%)
Asia Paciﬁc,
n (%)
North America,
n (%)
Latin America,
n (%)
Africa Middle
East, n (%)
Region Not
Speciﬁed, n (%)
Total (n ¼ 47),
n (%)
Maculopapular exanthema 18 (38.3) 2 (4.3) 4 (8.5) 5 (10.6) 1 (2.1) 1 (2.1) 31 (66.0)
Drug induced hypersensitivity
syndrome (DIHS)
14 (29.8) 6 (12.8) 3 (6.4) 4 (8.5) 2 (4.3) 1 (2.1) 30 (63.8)
Fixed drug eruption 14 (29.8) 3 (6.4) 2 (4.3) 4 (8.5) 4 (8.5) 2 (4.3) 29 (61.7)
AGEP 15 (31.9) 3 (6.4) 4 (8.5) 3 (6.4) 0 (0.0) 1 (2.1) 26 (55.3)
Stevens–Johnson syndrome 13 (27.7) 2 (4.3) 0 (0.0) 4 (8.5) 2 (4.3) 1 (2.1) 22 (46.8)
TEN 8 (17.0) 1 (2.1) 0 (0.0) 3 (6.4) 1 (2.1) 1 (2.1) 14 (29.8)
Immunobullous eruptions 8 (17.0) 1 (2.1) 0 (0.0) 2 (4.3) 0 (0.0) 1 (2.1) 12 (25.5)
Vasculitis 7 (14.9) 1 (2.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 8 (17.0)
Blood dyscracias 1 (2.1) 1 (2.1) 0 (0.0) 1 (2.1) 0 (0.0) 0 (0.0) 3 (6.4)
Percentage represents percentage of all 47 respondents who answered this question.
TABLE 8. Indications for DPTs
Europe,
n (%)
Asia Paciﬁc,
n (%)
North America,
n (%)
Latin America,
n (%)
Africa Middle
East, n (%)
Region Not
Speciﬁed, n (%)
Total (n ¼ 65),
n (%)
Exclude hypersensitivity (non-suggestive
history/non-speciﬁc symptoms)
25 (38.5) 10 (15.4) 4 (6.2) 4 (6.2) 2 (3.1) 5 (7.7) 50 (76.9)
Deﬁnitive diagnosis in suggestive
history with negative, non-conclusive
or non- available allergological tests
22 (33.8) 9 (13.8) 4 (6.2) 5 (7.7) 4 (6.2) 0 (0.0) 44 (67.7)
Exclude cross-reactivity of related drugs
in proven hypersensitivity
(e.g. cephalosporin in a penicillin
allergic individual)
22 (33.8) 8 (12.3) 4 (6.2) 3 (4.6) 2 (3.1) 2 (3.1) 41 (63.1)
Provide safe pharmacologically/
structurally
non-related drugs in proven
hypersensitivity (e.g. beta-lactams)
21 (32.3) 5 (7.7) 5 (7.7) 3 (4.6) 2 (3.1) 3 (4.6) 39 (60.0)
Percentage represents percentage of all 65 respondents who answered this question.
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for TEN and 9.2% used other immunosuppressive drugs
including cyclosporine. More than two thirds would consider
comanaging TEN patients with an intensivist/ burns unit60,61;
this may have been limited by the availability of such tertiary
specialty care in certain regions. Only 49.2% considered
comanagement with an ophthalmologist, suggesting that
a greater awareness of the ocular complications of SCAR
and the need for aggressive ocular immunomodulatory ther-
apy may be needed.62
HLA screening63 has been shown to be useful in prevent-
ing SCAR before the prescription of abacavir in whites,64 car-
bamazepine in Han Chinese or individuals of Asian ancestry,65
and allopurinol in Han Chinese.66 Only 17.1% of respondents
had access to HLA screening for drugs at high risk of causing
SCAR, with the majority (92.9%) screening for HLA B*5701
before prescribing abacavir, and 21.4% screening for HLA
B*1502 before prescribing carbamazepine in Asians. This
may have been due to lack of availability of rapid HLA screen-
ing kits in certain parts of Asia, or differences in local pharma-
covigilance requirements.67
There were several limitations to this survey, which was
highlighted by respondents. First, within large countries/
regions, the president/chair of the WAO afﬁliated society
may not have had ample opportunity to run the survey
through all members from different states/districts within the
6-week consultation period, especially where practices may
be heterogenous and in large countries/regions. Second,
interest and expertise in dealing with drug allergies also
varied within different countries/regions, as certain types of
drug allergies were looked after by organ-based specialists
rather than allergologists, for example, patients with SJS were
looked after by dermatologists in certain regions. In this
context, the survey may have inevitably been slightly skewed
toward obtaining/ receiving the results from the most dedicated
centers with speciﬁc research interests. For example, the use of
basophil activation test or LTT as diagnostic tools may not be
as common in clinical practice as it appears from the audit’s
results. Third, there were clinical practices in certain regions,
which were not covered by the questions used in the survey
(eg, delayed IDT readings for nonimmediate reactions).
Although this survey has shown the types of tests
available and practiced in various parts of the world, this need
not necessarily mean that the tests are uniformly useful. For
instance, patch tests, although carried out in many European
centers for nonimmediate reactions, are drug-speciﬁc and
reaction-speciﬁc and thus are more useful where certain types
of nonimmediate reactions predominate. The use of standard-
ized nomenclature, patient proﬁles, harmonization of test
procedures, measurements, and outcome measures are crucial
in improving the diagnostic modalities presently used in
evaluating drug hypersensitivity/ allergy, ﬁndings similarly
reﬂected in the Drug Ambassador Project carried out by the
European Network for Drug Allergy.68
CONCLUSIONS
This survey shows that even though well-established
international guidelines are available for the diagnosis and
management of drug allergy, practices vary across the different
regions of the world due to differences in allergology training,
practice setups, funding mechanisms, and resource limitations.
Nonetheless, the results of this survey will help facilitate
multicenter networking in education, practice, and resource
development in drug allergy/hypersensitivity. It is our hope that
the results of this survey will, through WAO, facilitate clinical,
educational, and research collaboration among the different
allergy centers with an interest in drug allergy/hypersensitivity.
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